[CAS NO. 4342-03-4] Dacarbazine
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [4342-03-4]
Catelog
HY-B0078
Brand
MCE
CAS
4342-03-4
DESCRIPTION [4342-03-4]
Overview
| MDL | MFCD00057167 |
|---|---|
| Molecular Weight | 182.18 |
| Molecular Formula | C6H10N6O |
| SMILES | O=C(C1=C(/N=N/N(C)C)NC=N1)N |
For research use only. We do not sell to patients.
3 Publications Citing Use of MCE
Summary
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00110994 | Bayer|Amgen |
Cancer|Melanoma
|
April 2005 | Phase 2 |
| NCT00002791 | Radiation Therapy Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Sarcoma
|
February 1997 | Phase 2 |
| NCT01692691 | Western Regional Medical Center |
Melanoma Metastatic
|
August 2012 | Phase 2 |
| NCT00130442 | Cellxpert Biotechnology Corp.|Medigen Biotechnology Corporation |
Melanoma
|
June 2005 | Phase 2 |
| NCT00003647 | Vical |
Stage IV Melanoma|Stage III Melanoma|Recurrent Melanoma
|
July 1998 | Phase 3 |
| NCT01712490 | Takeda|Seagen Inc. |
Hodgkin Lymphoma
|
November 9, 2012 | Phase 3 |
| NCT01534078 | Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|H. Lee Moffitt Cancer Center and Research Institute|Seagen Inc. |
Hodgkin Lymphoma
|
March 2012 | Phase 2 |
| NCT01404936 | M.D. Anderson Cancer Center|Schering-Plough |
Lymphoma
|
July 1996 | Phase 2 |
| NCT01152788 | NCIC Clinical Trials Group|Canadian Cancer Trials Group |
Melanoma
|
June 28, 2010 | Phase 2 |
| NCT00025064 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Lymphoma
|
January 2000 | Phase 2 |
| NCT04067037 | Henan Cancer Hospital |
Classical Hodgkin Lymphoma
|
August 26, 2019 | Phase 2 |
| NCT00504504 | M.D. Anderson Cancer Center|Genentech, Inc. |
Lymphoma
|
March 2001 | Phase 2 |
| NCT01376713 | Medical University of Vienna |
Stage III Melanoma|Stage IV Melanoma
|
June 2011 | Phase 2 |
| NCT04225390 | University of Erlangen-Nürnberg Medical School|University Hospital Regensburg|Wuerzburg University Hospital |
Immunotherapy
|
January 13, 2020 | Phase 2 |
| NCT00433459 | Christine Mauz-Körholz|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
January 2007 | Phase 3 |
| NCT00416377 | Children´s Cancer and Leukaemia Group|National Cancer Institute (NCI) |
Lymphoma
|
Not Applicable | |
| NCT00395070 | Vical |
Metastatic Melanoma
|
October 2006 | Phase 3 |
| NCT00003027 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Southwest Oncology Group|Cancer and Leukemia Group B |
Melanoma (Skin)
|
October 1997 | Phase 3 |
| NCT00070642 | Pfizer |
Carcinoma, Melanoma
|
December 2003 | Phase 2 |
| NCT00911443 | sigma-tau i.f.r. S.p.A. |
Malignant Melanoma
|
July 2002 | Phase 2 |
| NCT01542255 | Dartmouth-Hitchcock Medical Center |
Metastatic Melanoma
|
June 2010 | Phase 2 |
| NCT02298257 | The Lymphoma Academic Research Organisation |
HIV Infection|HIV-associated Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma
|
June 2015 | Phase 2 |
| NCT00864253 | Celgene|University of Arizona |
Malignant Melanoma
|
April 23, 2009 | Phase 3 |
| NCT03805022 | Institut Bergonié|Novartis|Chugai Pharma France |
Non-metastatic Soft-tissue Sarcoma|Resectable
|
February 14, 2019 | Phase 3 |
| NCT01100528 | Case Comprehensive Cancer Center |
Ciliary Body and Choroid Melanoma, Medium+Large Size|Ciliary Body and Choroid Melanoma, Small Size|Iris Melanoma|Recurrent Intraocular Melanoma
|
November 11, 2009 | Phase 2 |
| NCT01280565 | AB Science |
Metastatic Melanoma
|
January 2011 | Phase 3 |
| NCT00920153 | French Innovative Leukemia Organisation |
Lymphoma
|
May 2008 | Phase 3 |
| NCT00005090 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B |
Lymphoma
|
April 2000 | Phase 3 |
| NCT00041210 | Mount Vernon Cancer Centre at Mount Vernon Hospital|National Cancer Institute (NCI) |
Lymphoma
|
October 2001 | Phase 3 |
| NCT01055522 | Philogen S.p.A.|Eudax S.r.l. |
Metastatic Melanoma
|
June 2008 | Phase 2 |
| NCT01868451 | Memorial Sloan Kettering Cancer Center|Seagen Inc.|University of Rochester|City of Hope Medical Center|Stanford University |
Hodgkin Lymphoma
|
May 2013 | Not Applicable |
| NCT00257205 | AstraZeneca |
Melanoma
|
March 2006 | Phase 3 |
| NCT03331341 | University of Washington |
Classical Hodgkin Lymphoma
|
January 9, 2019 | Phase 2 |
| NCT01835145 | National Cancer Institute (NCI)|Exelisis |
Recurrent Uveal Melanoma|Stage III Uveal Melanoma AJCC v7|Stage IIIA Uveal Melanoma AJCC v7|Stage IIIB Uveal Melanoma AJCC v7|Stage IIIC Uveal Melanoma AJCC v7|Stage IV Uveal Melanoma AJCC v7
|
July 31, 2013 | Phase 2 |
| NCT03226249 | Northwestern University|National Cancer Institute (NCI)|Merck Sharp & Dohme LLC |
Classical Hodgkin Lymphoma|Lymphocyte-Depleted Classical Hodgkin Lymphoma|Lymphocyte-Rich Classical Hodgkin Lymphoma|Mixed Cellularity Classical Hodgkin Lymphoma|Nodular Sclerosis Classical Hodgkin Lymphoma
|
November 9, 2017 | Phase 2 |
| NCT00006200 | National Center for Research Resources (NCRR) |
Melanoma
|
Phase 2 | |
| NCT00089544 | National Cancer Institute (NCI)|Radiation Therapy Oncology Group |
Recurrent Adult Soft Tissue Sarcoma|Stage I Adult Soft Tissue Sarcoma AJCC v7|Stage II Adult Soft Tissue Sarcoma AJCC v7|Stage III Adult Soft Tissue Sarcoma AJCC v7
|
June 17, 2004 | Phase 2 |
| NCT04221035 | Gustave Roussy, Cancer Campus, Grand Paris |
High-Risk Neuroblastoma
|
November 5, 2019 | Phase 3 |
| NCT00533702 | Eli Lilly and Company |
Metastatic Malignant Melanoma
|
November 2007 | Phase 2 |
| NCT01133977 | Eisai Inc.|Quintiles, Inc. |
Stage IV Melanoma
|
April 2010 | Phase 1|Phase 2 |
| NCT00849875 | GlaxoSmithKline |
Melanoma
|
May 26, 2009 | Phase 2 |
| NCT01227889 | GlaxoSmithKline |
Cancer
|
December 23, 2010 | Phase 3 |
| NCT01164007 | Hoffmann-La Roche |
Malignant Melanoma
|
June 30, 2006 | Phase 2 |
| NCT02545075 | Bristol-Myers Squibb |
Melanoma
|
October 31, 2015 | Phase 3 |
| NCT00002669 | European Organisation for Research and Treatment of Cancer - EORTC |
Melanoma (Skin)
|
June 1995 | Phase 2 |
| NCT04727242 | Stanford University |
LMS - Leiomyosarcoma|Uterine Leiomyosarcoma
|
January 28, 2021 | Phase 2 |
| NCT04893356 | National Cancer Institute, Naples |
Sarcoma
|
January 20, 2021 | |
| NCT00516802 | AstraZeneca|KuDOS Pharmaceuticals Limited |
Melanoma Neoplasms
|
January 2007 | Phase 1 |
| NCT01920932 | St. Jude Children´s Research Hospital|Seagen Inc. |
Stage II Childhood Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma
|
August 12, 2013 | Phase 2 |
| NCT01974752 | AstraZeneca |
Metastatic|Uveal Melanoma
|
April 2014 | Phase 3 |
| NCT00308607 | University of Turku |
Metastatic Melanoma
|
August 2005 | Phase 2 |
| NCT03233347 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Ann Arbor Stage I Hodgkin Lymphoma|Ann Arbor Stage IA Hodgkin Lymphoma|Ann Arbor Stage IB Hodgkin Lymphoma|Ann Arbor Stage II Hodgkin Lymphoma|Ann Arbor Stage IIA Hodgkin Lymphoma|Ann Arbor Stage IIB Hodgkin Lymphoma|Classic Hodgkin Lymphoma
|
October 13, 2017 | Phase 2 |
| NCT01569204 | University of Cologne |
Hodgkin Lymphoma
|
October 2012 | Phase 2 |
| NCT00496223 | H. Lee Moffitt Cancer Center and Research Institute|Pfizer |
Melanoma
|
September 2006 | Phase 1|Phase 2 |
| NCT03712202 | City of Hope Medical Center|National Cancer Institute (NCI) |
Ann Arbor Stage I Hodgkin Lymphoma|Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IA Hodgkin Lymphoma|Ann Arbor Stage IB Hodgkin Lymphoma|Ann Arbor Stage II Hodgkin Lymphoma|Ann Arbor Stage IIA Hodgkin Lymphoma|Ann Arbor Stage IIB Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma|Ann Arbor Stage I Lymphocyte-Depleted Classic HL|Ann Arbor Stage II Lymphocyte-Depleted Classic HL|Ann Arbor Stage II Mixed Cellularity Classic HL|Ann Arbor Stage II Nodular Sclerosis Classic HL
|
November 28, 2018 | Phase 2 |
| NCT05269355 | PTC Therapeutics |
Leiomyosarcoma
|
May 23, 2022 | Phase 2|Phase 3 |
| NCT01390584 | ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group |
Lymphoma
|
April 2, 2012 | Phase 2 |
| NCT03277924 | Grupo Espanol de Investigacion en Sarcomas |
Soft Tissue Sarcoma|Bone Sarcoma
|
May 31, 2017 | Phase 1|Phase 2 |
| NCT03407144 | Merck Sharp & Dohme LLC |
Hodgkin Lymphoma
|
April 9, 2018 | Phase 2 |
| NCT03159897 | Fondazione Italiana Linfomi ONLUS |
Hodgkin Lymphoma
|
August 1, 2017 | Phase 3 |
| NCT01476410 | Northwestern University|Robert H. Lurie Cancer Center|Seagen Inc. |
Adult Lymphocyte Depletion Hodgkin Lymphoma|Adult Lymphocyte Predominant Hodgkin Lymphoma|Adult Mixed Cellularity Hodgkin Lymphoma|Adult Nodular Sclerosis Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma
|
November 2011 | Phase 2 |
| NCT00004010 | Children´s Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
October 1999 | Phase 2 |
| NCT00410631 | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Neuroblastoma
|
October 2004 | Phase 3 |
| NCT03430297 | Shanghai Junshi Bioscience Co., Ltd. |
Metastatic Melanoma|Unresectable Melanoma
|
February 2, 2018 | Phase 3 |
| NCT01721772 | Bristol-Myers Squibb |
Melanoma
|
January 18, 2013 | Phase 3 |
| NCT05008224 | Merck Sharp & Dohme LLC |
Classical Hodgkin Lymphoma
|
October 7, 2021 | Phase 2 |
| NCT03527628 | King Abdullah International Medical Research Center |
Classical Hodgkin Lymphoma|Hodgkin Lymphoma (Category)|Hodgkin Disease|Hodgkin Lymphoma
|
January 1, 2018 | Phase 2 |
| NCT00226473 | Dermatologic Cooperative Oncology Group |
Metastatic Melanoma
|
September 2001 | Phase 4 |
| NCT00813449 | Simcere Pharmaceutical Co., Ltd |
Advanced Melanoma|Untreated Patients
|
August 2008 | Phase 2 |
| NCT00072124 | National Cancer Institute (NCI) |
Melanoma (Skin)
|
September 2003 | Phase 3 |
| NCT00002882 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Melanoma|Skin Cancer
|
November 1995 | Phase 3 |
| NCT01614301 | University of Regensburg|ClinAssess GmbH |
Advanced Melanoma
|
May 2012 | Phase 1|Phase 2 |
| NCT01060904 | Seagen Inc.|Millennium Pharmaceuticals, Inc. |
Disease, Hodgkin
|
January 2010 | Phase 1 |
| NCT00526318 | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Neuroblastoma
|
January 2007 | Not Applicable |
| NCT00091572 | Merck Sharp & Dohme LLC|European Organisation for Research and Treatment of Cancer - EORTC |
Melanoma
|
October 20, 2004 | Phase 3 |
| NCT05404945 | University of Virginia|Merck Sharp & Dohme LLC |
Classical Hodgkin Lymphoma
|
July 26, 2022 | Phase 2 |
| NCT04638790 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia |
Hodgkin Lymphoma, Adult
|
February 1, 2020 | Phase 3 |
| NCT03004833 | University of Cologne |
Classical Hodgkin Lymphoma
|
February 21, 2017 | Phase 2 |
| NCT01251107 | Fondazione Michelangelo |
Hodgkin Lymphoma
|
March 2000 | Phase 3 |
| NCT03761095 | PTC Therapeutics |
Leiomyosarcoma
|
March 13, 2019 | Phase 1 |
| NCT00003389 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) |
Lymphoma
|
April 1999 | Phase 3 |
| NCT00033644 | Gynecologic Oncology Group|National Cancer Institute (NCI)|GOG Foundation |
Sarcoma
|
March 2002 | Phase 2 |
| NCT01468740 | Harlachinger Krebshilfe e.V.|Deutsche AIDS Gesellschaft e.V. |
HIV-associated Hodgkin Lymphoma
|
March 2004 | Phase 2 |
| NCT01763164 | Pfizer |
Metastatic or Unresectable Cutaneous Melanoma
|
July 12, 2013 | Phase 3 |
| NCT01132807 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
Lymphoma
|
May 2010 | Phase 2 |
| NCT00066196 | MedImmune LLC |
Melanoma|Malignant Metastatic Melanoma
|
August 2003 | Phase 2 |
| NCT01705392 | Haukeland University Hospital|The Norwegian Melanoma Group|Norwegian Cancer Society |
Metastatic Malignant Melanoma|Unresectable Malignant Melanoma
|
January 2013 | Phase 2 |
| NCT02661503 | University of Cologne |
Classical Hodgkin Lymphoma
|
July 2016 | Phase 3 |
| NCT00654732 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) |
Classic Hodgkin Lymphoma|Lugano Classification Stage III Hodgkin Lymphoma AJCC v8|Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
|
March 19, 2008 | Phase 2 |
| NCT00003421 | Medical Research Council|National Cancer Institute (NCI) |
Lymphoma
|
June 1998 | Phase 3 |
| NCT00580320 | Virginia Commonwealth University |
Melanoma|Soft Tissue Sarcoma|Parathyroid Carcinoma|Small Cell Carcinoma of the Lung|Carcinoid Tumors
|
September 2004 | Phase 1 |
| NCT01692678 | Xian-Janssen Pharmaceutical Ltd. |
Advanced or Metastatic Liposarcoma or Leiomyosarcoma
|
August 7, 2012 | Phase 3 |
| NCT02797717 | GALIA AVRAHAMI|University of Giessen|Rabin Medical Center |
Classical Hodgkins Lymphoma in Children and Adolescents.
|
November 2015 | Not Applicable |
| NCT03907488 | National Cancer Institute (NCI) |
Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IIIA Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma|Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma|Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Classic Hodgkin Lymphoma|Lymphocyte-Rich Classic Hodgkin Lymphoma
|
July 19, 2019 | Phase 3 |
| NCT00615160 | Michael Weichenthal|University Hospital Schleswig-Holstein |
Melanoma
|
December 2006 | Phase 1|Phase 2 |
| NCT01343277 | Janssen Research & Development, LLC|PharmaMar |
Advanced Liposarcoma or Leiomyosarcoma
|
June 2011 | Phase 3 |
| NCT00498979 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) |
Stage IV Melanoma
|
May 2007 | Phase 1 |
| NCT01327885 | Eisai Inc. |
Soft Tissue Sarcoma
|
March 10, 2011 | Phase 3 |
| NCT04685616 | University College, London|Takeda|Canadian Cancer Trials Group |
Hodgkin Lymphoma
|
April 14, 2022 | Phase 3 |
| NCT00518895 | Genta Incorporated |
Melanoma
|
July 2007 | Phase 3 |
| NCT00004141 | University of Chicago|National Cancer Institute (NCI) |
Melanoma (Skin)
|
August 1998 | Phase 2 |
| NCT00936221 | AstraZeneca |
Melanoma
|
July 2009 | Phase 2 |
| NCT00553618 | University of Louisville|James Graham Brown Cancer Center |
Metastatic Melanoma
|
August 2007 | Phase 2 |
| NCT00991250 | SentoClone AB |
Malignant Melanoma
|
October 2009 | Phase 2 |
| NCT00779714 | University of Wuerzburg|Hiege-Stiftung gegen Hautkrebs|medac GmbH|DCS Innovative Diagnostik Systeme |
Melanoma
|
October 2008 | Phase 3 |
| NCT04733183 | Philogen S.p.A. |
Soft Tissue Sarcoma
|
August 28, 2020 | Phase 2 |
| NCT01551459 | The Clatterbridge Cancer Centre NHS Foundation Trust|Cancer Research UK|Pfizer |
Metastatic Uveal Melanoma
|
October 2010 | Phase 2 |
| NCT00597038 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb |
Metastatic Melanoma
|
November 2007 | Phase 1|Phase 2 |
| NCT00002802 | Children´s Hospital Medical Center, Cincinnati|National Cancer Institute (NCI) |
Neuroblastoma
|
July 1990 | Phase 3 |
| NCT01681212 | Bristol-Myers Squibb |
Melanoma
|
October 2012 | Phase 2 |
| NCT00559026 | Istituto Superiore di Sanità|Regina Elena Cancer Institute|University of Rome Tor Vergata |
Melanoma
|
September 2004 | Phase 1 |
| NCT00016263 | Genta Incorporated|National Cancer Institute (NCI) |
Melanoma (Skin)
|
July 2000 | Phase 3 |
| NCT02181738 | Bristol-Myers Squibb |
Hodgkin Disease
|
August 12, 2014 | Phase 2 |
| NCT00837148 | Memorial Sloan Kettering Cancer Center|Bayer |
Sarcoma|Synovial Sarcoma|Leiomyosarcoma|Malignant Peripheral Nerve Sheath Tumor
|
February 2009 | Phase 2 |
| NCT00070343 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Melanoma (Skin)
|
August 2003 | Not Applicable |
| NCT03023124 | Italian Sarcoma Group |
Solitary Fibrous Tumors
|
March 4, 2018 | Phase 2 |
| NCT00802880 | Washington University School of Medicine |
Sarcoma
|
March 2009 | Phase 2 |
| NCT04200040 | OrienGene Biotechnology Ltd. |
Melanoma (Skin)
|
August 27, 2017 | Phase 2 |
| NCT03016819 | Advenchen Laboratories, LLC |
Alveolar Soft Part Sarcoma|Leiomyosarcoma|Synovial Sarcoma|Soft-Tissue Sarcoma
|
August 15, 2017 | Phase 3 |
| NCT01143402 | National Cancer Institute (NCI) |
Iris Melanoma|Medium+Large Size Posterior Uveal Melanoma|Ocular Melanoma With Extraocular Extension|Recurrent Uveal Melanoma|Small Size Posterior Uveal Melanoma|Stage IV Uveal Melanoma
|
June 2010 | Phase 2 |
| NCT02505269 | Massachusetts General Hospital|Seagen Inc. |
Hodgkin Lymphoma
|
August 7, 2015 | Phase 2 |
| NCT02292979 | The Lymphoma Academic Research Organisation|Millennium Pharmaceuticals, Inc. |
Hodgkin Lymphoma
|
March 2015 | Phase 2 |
| NCT02190838 | N.N. Petrov National Medical Research Center of Oncology |
Melanoma
|
April 2014 | Phase 2 |
| NCT00017225 | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany|National Cancer Institute (NCI) |
Neuroblastoma
|
May 1997 | Phase 2 |
| NCT02979522 | Takeda |
Hodgkin Disease
|
September 6, 2017 | Phase 1|Phase 2 |
| NCT03033914 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb|Barbara Ann Karmanos Cancer Institute|British Columbia Cancer Agency |
Hodgkin Lymphoma
|
January 25, 2017 | Phase 1|Phase 2 |
| NCT00002561 | NCIC Clinical Trials Group|Eastern Cooperative Oncology Group|Canadian Cancer Trials Group |
Hodgkin Lymphoma
|
January 25, 1994 | Phase 3 |
| NCT00822120 | Southwest Oncology Group|National Cancer Institute (NCI) |
Lymphoma|Nonneoplastic Condition
|
July 2009 | Phase 2 |
| NCT01721746 | Bristol-Myers Squibb |
Unresectable or Metastatic Melanoma
|
December 21, 2012 | Phase 3 |
| NCT00324155 | Bristol-Myers Squibb|Medarex |
Melanoma
|
August 2006 | Phase 3 |
| NCT00000626 | National Institute of Allergy and Infectious Diseases (NIAID)|Amgen |
HIV Infections|Hodgkin´s Disease
|
Phase 2 | |
| NCT00796991 | Bristol-Myers Squibb|Medarex |
Advanced Melanoma
|
February 2009 | Phase 1 |
| NCT00412581 | M.D. Anderson Cancer Center|Celgene Corporation |
Melanoma
|
September 2005 | Phase 1 |
| NCT00023738 | Radiation Therapy Oncology Group|National Cancer Institute (NCI) |
Sarcoma
|
August 2001 | Phase 1|Phase 2 |
| NCT02684708 | University of Giessen|Deutsche Krebshilfe e.V., Bonn (Germany)|Euronet Worldwide |
Classical Hodgkin Lymphoma
|
October 1, 2015 | Phase 3 |
| NCT00600496 | AstraZeneca |
Breast Cancer|Breast Neoplasms|Colon Cancer|Colonic Cancer|Colon Neoplasms|Lung Cancer|Melanoma|Kidney Cancer
|
December 14, 2007 | Phase 1 |
| NCT03646123 | Seagen Inc.|Bristol-Myers Squibb |
Hodgkin Lymphoma
|
January 28, 2019 | Phase 2 |
| NCT01693068 | EMD Serono|Merck KGaA, Darmstadt, Germany |
N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma
|
December 5, 2012 | Phase 2 |
| NCT01704287 | Merck Sharp & Dohme LLC |
Malignant Melanoma
|
November 20, 2012 | Phase 2 |
| NCT03070392 | Immunocore Ltd |
Uveal Melanoma
|
October 16, 2017 | Phase 2 |
| NCT00246012 | Centocor, Inc.|Janssen-Cilag Farmaceutica, S.R.L. |
Melanoma
|
May 2005 | Phase 1|Phase 2 |
| NCT00049595 | European Organisation for Research and Treatment of Cancer - EORTC|Lymphoma Trials Office|Lymphoma Study Association|Grup per l´Estudi dels Limfomes de Catalunya i Balears|NCIC Clinical Trials Group|Australasian Leukaemia and Lymphoma Group|Nordic Lymphoma Group |
Lymphoma
|
August 2002 | Phase 3 |
| NCT01716806 | Seagen Inc.|Bristol-Myers Squibb |
Hodgkin Disease|Peripheral T Cell Lymphoma
|
October 31, 2012 | Phase 2 |
| NCT03517137 | European Organisation for Research and Treatment of Cancer - EORTC |
Advanced Hodgkin Lymphoma
|
August 1, 2019 | Phase 2 |
| NCT00006237 | Southwest Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|Cancer and Leukemia Group B|Children´s Oncology Group |
Melanoma (Skin)
|
August 2000 | Phase 3 |
| NCT03279601 | Peking University |
Neuroendocrine Tumors
|
September 1, 2017 | Phase 2 |
| NCT00416832 | Christine Mauz-Körholz|Martin-Luther-Universität Halle-Wittenberg |
Lymphoma
|
November 2002 | Phase 2 |
| NCT00678327 | University College, London|Cancer Research UK|Cancer Research UK & UCL Cancer Trials Centre |
Lymphoma
|
August 29, 2008 | Phase 3 |
| NCT01359956 | National Cancer Institute, Naples |
Malignant Melanoma|Recurrent Melanoma
|
April 2002 | Phase 3 |
| NCT01771107 | National Cancer Institute (NCI) |
AIDS-Related Hodgkin Lymphoma|Ann Arbor Stage II Hodgkin Lymphoma|Ann Arbor Stage IIA Hodgkin Lymphoma|Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage III Hodgkin Lymphoma|Ann Arbor Stage IIIA Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Classic Hodgkin Lymphoma|HIV Infection
|
March 7, 2013 | Phase 1|Phase 2 |
| NCT00354523 | M.D. Anderson Cancer Center|Novartis Pharmaceuticals |
Solid Tumor|Thyroid Cancer
|
December 2004 | Phase 1|Phase 2 |
| NCT00369681 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI) |
Lymphoma
|
May 2006 | Phase 2 |
| NCT01006980 | Hoffmann-La Roche |
Malignant Melanoma
|
January 2010 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
In Vitro:
DMSO : 5 mg/mL ( 27.45 mM ; ultrasonic and warming and heat to 60°C)
H 2 O : 1 mg/mL ( 5.49 mM ; Need ultrasonic and warming)
Preparing
Stock Solutions
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.4891 mL | 27.4454 mL | 54.8908 mL |
| 5 mM | 1.0978 mL | 5.4891 mL | 10.9782 mL |
| 10 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL |
*
Please refer to the solubility information to select the appropriate solvent.
In Vivo:
-
1.
Add each solvent one by one: 50% PEG300 >> 50% saline
Solubility: 5 mg/mL (27.45 mM); Suspended solution; Need ultrasonic
-
2.
Add each solvent one by one: PBS
Solubility: 2 mg/mL (10.98 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
*
All of the co-solvents are available by MCE.
References
- [1] Al-Badr AA, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016;41:323-77.
- [2] Rojo JM, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29(5):345-51.
- [3] Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19(1): p. 21-34.
Synonyms
1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazen-1-yl)-
Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno)-
1H-Imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazenyl)-
Imidazole-4(or 5)-carboxamide, 5(or 4)-(3,3-dimethyl-1-triazeno)-
5-(3,3-Dimethyl-1-triazen-1-yl)-1H-imidazole-4-carboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5(or 4)-(3,3-Dimethyl-1-triazeno)imidazole-4(or 5)carboxamide
5(4)-(3,3-Dimethyl-1-triazeno)imidazole-4(5)-carboxamide
4(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
Dacarbazine
NSC 45388
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
DTIC
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
Biocarbazine R
Deticene
5-(3,3′-Dimethyl-1-triazeno)imidazole-4-carboxamide
Dacarbasine
DTIE
DTIC-Dome
NCI C04717
ICDT
ICDMT
DIC
Detimedac
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.